EQT Life Sciences and Sectoral Asset Management led a $42m Series D funding round in Phagenesis.

EQT Life Sciences, a healthcare investor, and Sectoral Asset Management, an industry specialist in managing global investment portfolios in the healthcare sector, led a $42m Series D funding round in Phagenesis, a medical devices company, which specializes in the treatment of swallowing disorders. “This investment from a highly experienced international investor syndicate will accelerate access to and adoption of our therapy,” Reinhard Krickl, Phagenesis CEO.